Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Neoplasm Metastasis 2Medulloblastoma 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 16Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioma × LY2940680 × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡